Biotech & Life Sciences InvestmentCibus's Entire Licensing Pipeline Hinges on Gene-Editing Claims That Lack Commercial-Scale ProofSalvado•Jun 11, 2026
Pharma & BiotechCellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027ViaNews Editorial Team (Finance)•Feb 20, 2026
